Cite
Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.
MLA
Yu, H. A., et al. “Translational Insights and Overall Survival in the U31402-A-U102 Study of Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC.” Annals of Oncology, vol. 35, no. 5, May 2024, pp. 437–47. EBSCOhost, https://doi.org/10.1016/j.annonc.2024.02.003.
APA
Yu, H. A., Baik, C., Kim, D.-W., Johnson, M. L., Hayashi, H., Nishio, M., Yang, J. C.-H., Su, W.-C., Gold, K. A., Koczywas, M., Smit, E. F., Steuer, C. E., Felip, E., Murakami, H., Kim, S.-W., Su, X., Sato, S., Fan, P.-D., Fujimura, M., & Tanaka, Y. (2024). Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC. Annals of Oncology, 35(5), 437–447. https://doi.org/10.1016/j.annonc.2024.02.003
Chicago
Yu, H.A., C. Baik, D.-W. Kim, M.L. Johnson, H. Hayashi, M. Nishio, J.C.-H. Yang, et al. 2024. “Translational Insights and Overall Survival in the U31402-A-U102 Study of Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC.” Annals of Oncology 35 (5): 437–47. doi:10.1016/j.annonc.2024.02.003.